Keyphrases
Glucagon
90%
GIP Receptor
61%
Glucose-dependent Insulinotropic Polypeptide
60%
Insulin Secretion
57%
Glucagon-like
55%
Glucagon-like peptide-1 (GLP-1)
52%
Receptor Antagonist
44%
Somatostatin
39%
Proglucagon
35%
Rodents
25%
Glucagon-like peptide-1 Receptor (GLP-1R)
23%
Insulin
21%
Blood Glucose
21%
Healthy Individuals
20%
Diabetes
20%
Rat Colon
19%
Delta Cell
19%
Competitive Antagonist
19%
Glucagon Signaling Pathway
19%
Receptor Subtypes
19%
Placebo-controlled
19%
Peptide YY
19%
Long-term Disability
19%
Sequester
19%
Islet
19%
High-affinity Binding
19%
Short-chain Fatty Acids
19%
G Protein
19%
Bile Acids
19%
GLP-1 Secretion
19%
Resin
19%
Glucose-lowering Drugs
19%
Internalization Efficiency
19%
Antidiabetic Agents
19%
Decretin
19%
Cell Control
19%
Sevelamer
19%
Residence Time
19%
Receptor Desensitization
19%
Oxyntomodulin
19%
Primates
19%
Intestinal L Cells
19%
Hepatic Glucose Production
19%
High Affinity
17%
Type 2 Diabetic Patients
17%
GIP Receptor Antagonist
16%
Competition Binding
15%
Biochemistry, Genetics and Molecular Biology
Gastric Inhibitory Polypeptide
100%
Glucagon
66%
Glucagon-Like Peptide-1
61%
Insulin Release
43%
Secretion (Process)
42%
Receptor Antagonist
41%
Gastric Inhibitory Polypeptide Receptor
40%
Glucose Blood Level
29%
Agonist
28%
Internalization
24%
Glucagon-Like Peptide-2
20%
Colon
19%
Peptide YY
19%
Bone Turnover
19%
G Protein
19%
Short-Chain Fatty Acid
19%
Somatostatin Cell
19%
Bile Acid
19%
Receptor down Regulation
19%
Neuromedin U
19%
Binding Affinity
19%
Gluconeogenesis
19%
Retention Time
19%
Enteroglucagon
19%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
99%
Glucagon-Like Peptide-1
61%
Receptor Antagonist
45%
Placebo
43%
Gastric Inhibitory Polypeptide Receptor
42%
Receptor
40%
Glucagon
32%
Glucagon Like Peptide 2
20%
Proglucagon
19%
Oxyntomodulin
19%
Sevelamer
19%
Bile Acid
19%
Desensitization
19%
Short Chain Fatty Acid
19%
Peptide YY
19%
Antidiabetic Agent
19%
